Brief: Captor Therapeutics Makes Progress In Cancer Treatment Development

Captor Therapeutics SA

25/02/2022 07:21

Feb 25 (Reuters) - Captor Therapeutics SA  CTXP.WA :
    * SAID ON THURSDAY IT HAS MADE PROGRESS IN RESEARCH WORK OF
DEVELOPMENT OF CANCER TREATMENT MEDICINE (CT-03 PROJECT)
    * THE DEVELOPED MEDICINE COULD HAVE POTENTIAL TO INDUCE
REDUCTION
OF IMPLANTED TUMORS IN MICE HAEMATOLOGICAL TUMORS, SCLC, NSCLC
AND TNBC
    * THE CHEMICAL SUBSTANCE RESEARCHED HAS PROVED TO HAVE
ABILITY TO
REDUCE TUMORS IN TESTED MICE SPECIES
    * SAYS THESE RESULTS REPRESENT MILESTONE TOWARDS SELECTION
OF
CLINICAL CANDIDATE
    * THE RESULTS OF BOTH STUDIES HAVE PROVED THAT THE LEADING
CHEMICAL SUBSTANCE CT-03 CAUSES EFFECTIVE DEGRADATION OF MCL-1
PROTEIN IN THE HUMAN CANCER CELLS INJECTED TO TESTED ANIMALS,
INDUCES APOPTOSIS, AND AS A RESULT OF THAT IT LEADS TO REDUCTION
OR REGRESSION OF TUMOURS
    * THE ABOVEMENTIONED RESULTS HAVE ALSO PROVED THE VALIDITY
OF
CONTINUED DEVELOPMENT OF CT-03 DEGRADERS WITH AIM OF CHOOSING
CLINICAL CANDIDATE AND IMPLEMENTING IT INTO THE PHASE OF
IND-ENABLING STUDIES (RESEARCH AND APPLICATION OF NEW TREATMENT)

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nEMnyJ9na
 Further company coverage:  CTXP.WA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))